Am J Transplant, Volume 20, Suppl 3 Archives - Page 217 of 223 - ATC Abstracts

2020 American Transplant Congress
Posttransplant Program Evaluations: Long-Term Outcomes are More Relevant to Patients Than Short-Term Outcomes
A. Wey, N. Salkowski, M. Skeans, B. Kasiske, A. Israni, J. Snyder
SRTR, Minneapolis, MN
*Purpose: Posttransplant evaluations with 1-year follow-up are criticized for not identifying clinically meaningful differences between programs, not being the right outcome for patients, or including…
2020 American Transplant Congress
Impact of Functional Status on Outcomes of Simultaneous Pancreas-Kidney Transplantation: Risks and Opportunities for Patient Benefit
K. Lentine¹, T. Alhamad², M. Cooper³, Z. Zhang⁴, K. Woodside⁵, D. Dadhania⁶, S. Chang², D. Axelrod⁷, M. Schnitzler⁴, R. Ouseph¹, J. Snyder⁸, B. Kasiske⁸, R. Parsons⁹
¹Department of Medicine, Saint Louis University, Saint Louis, MO, ²Washington Univ, Seattle, WA, ³Georgetown Univ, Washington, DC, ⁴Saint Louis University, Saint Louis, MO, ⁵Univ of Michigan, Ann Arbor, MI, ⁶Weill Cornell, New York, NY, ⁷Univ of Iowa, Iowa City, IA, ⁸SRTR, Minneapolis, MN, ⁹Emory, Atlanta, GA
*Purpose: The impact of functional status on survival among simultaneous pancreas-kidney transplant (SPKT) candidates and recipients is not well described.*Methods: We examined national Scientific Registry…
2020 American Transplant Congress
A Data-Driven Approach to Defining the Volume-Outcome Relationship in Liver Transplantation
M. D. Bailey, E. L. Godfrey, W. C. Frankel, A. Rana
Baylor College of Medicine, Houston, TX
*Purpose: Patients with end-stage liver disease (ESLD) who undergo liver transplantation experience significant survival benefit, with a 1-year survival rate after liver transplantation of 91%.…
2020 American Transplant Congress
The Efficacy of Spheroidal Hepatocyte in Hepatocyte Transplantation
K. Shibuya, M. Watanabe, R. Kanazawa, Y. Ganchiku, R. Goto, A. Taketomi
Department of Gastroenterological Surgery Ⅰ Hokkaido University Graduate School, Sapporo, Japan
*Purpose: Hepatocyte transplantation (HCTx) has been expected as a next generation cell therapy alternative to liver transplantation. Following HCTx, the liver function improves in many…
2020 American Transplant Congress
Causes of Kidney Allograft Loss (GL) in the Current Era of Donor-Specific Alloantibody (DSA) Testing
M. Merzkani¹, X. Benavides¹, M. D'Costa¹, B. Smith¹, W. Park¹, A. Rule¹, H. Chakkera², K. Reddy², M. Alexander¹, H. Amer¹, M. El Ters¹, C. Schinstock¹, R. Heilman², A. Bentall¹, M. Stegall¹
¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Scottsdale, AZ
*Purpose: The goal of this study was to examine the causes and risk factors (RF) for renal GL in the era since the widespread adoption…
2020 American Transplant Congress
A Proof-of-Principle Study to Evaluate Autologous Hematopoietic Stem Cell Transplantation for Allogeneic Organ Transplant Tolerance (ASCOTT)
A. Chruscinski¹, S. Juvet¹, S. Moshkelgosha¹, E. Renner¹, L. Lilly¹, N. Selzner¹, C. Bredeson², O. Adeyi¹, S. Fischer¹, A. Demetris³, J. Zhang¹, M. Epstein¹, A. Clement², K. Khalili¹, Z. Galvin¹, A. Humar¹, T. Kim¹, K. Tinckham¹, T. Yi¹, G. Levy¹, H. Atkins²
¹Multi-Organ Transplantation, University Health Network, Toronto, ON, Canada, ²The Ottawa Hospital, Ottawa, ON, Canada, ³University of Pittsburgh, Pittsburgh, PA
*Purpose: Long-term survival of recipients of solid organ transplants is limited by chronic rejection, disease recurrence and immunosuppression-induced toxicity. Self-tolerance is established after autologous hematopoietic…
2020 American Transplant Congress
History of Coronary Artery Disease Predicts Inferior Survival in Liver Transplant Recipients of Advanced Age in a Large Multicenter U.S. Cohort
M. German¹, A. Hristov¹, A. Lee¹, F. Osman¹, A. Kwong², D. Devuni³, C. Wang⁴, J. Boike⁵, J. Jo⁵, L. VanWagner⁵, M. Serper⁶, R. Sharma⁷, E. Verna⁷, J. Shor³, A. Koteish⁸, G. Sehmbey⁹, A. Seetharam⁹, N. John², Y. Patel¹⁰, M. Kappus¹⁰, T. Couri¹¹, S. Paul¹¹, R. Salgia¹², Q. Nhu¹³, C. Frenette¹³, J. Lai⁴, A. Goel², E. Spengler¹
¹U of Wisconsin, Madison, WI, ²Stanford, Palo Alto, CA, ³U of Massachusetts, Worcester, MA, ⁴U of California, San Francisco, CA, ⁵Northwestern, Chicago, IL, ⁶U of Pennsylvania, Philadelphia, PA, ⁷Columbia, New York, NY, ⁸Florida Hospital, Orlando, FL, ⁹U of Arizona, Phoenix, AZ, ¹⁰Duke, Durham, NC, ¹¹U of Chicago, Chicago, IL, ¹²Henry Ford Hospital, Detroit, MI, ¹³Scripps, San Diego, CA
*Purpose: Coronary artery disease (CAD) is common in patients of advanced age and does not preclude liver transplantation (LT) if adequately treated. We aimed to…
2020 American Transplant Congress
MTOR-Inhibitor Regimens and Malignancy after Kidney Transplantation: Can the Risk Be Modified by Considering Human Leukocyte Antigen (HLA) Mismatch in Immunosuppression Selection?
A. Santos¹, C. Chen¹, K. Alquadan², M. A. Leghrouz², X. Wen³
¹University of Florida, Gainesville, FL, ²Division of Nephrology, Hypertension, & Renal Transplantation, University of Florida, Gainesville, FL, ³Department of Pharmacy Practice, University of Rhode Island, Kingston, RI
*Purpose: We investigated the outcomes of mammalian target of rapamycin inhibitor (MTORI) regimens in adult kidney transplant (KT) recipients (KTRs) in categories of donor/recipient pre-transplant…
2020 American Transplant Congress
Quantifiable Loss of Insulin Secretory Granules in Delayed Endocrine Pancreas Graft Function in Comparison to Controls
C. B. Drachenberg¹, J. C. Papadimitriou¹, J. R. Scalea², A. Haririan³, R. Ugarte³, S. Niederhaus², J. Bromberg²
¹Pathology, University of Maryland, Baltimore, MD, ²Surgery, University of Maryland, Baltimore, MD, ³Medicine, University of Maryland, Baltimore, MD
*Purpose: Approximately 1/3 of pancreas transplant fail to gain glycemic control in the first days/weeks posttransplantation, requiring exogenous insulin administration. Delayed endocrine pancreas graft function…
2020 American Transplant Congress
Association of Kidney Allograft Fibrosis-Associated Proteins with Chronic Lung Allograft Dysfunction
S. Farkona¹, G. Berra², Z. Mohammed-Ali¹, P. Ly², L. Levy², B. Renaud-Picard², G. Zehong², T. Daigneault², S. Juvet², C. McEvoy¹, S. Clotet-Freixas¹, T. Martinu², A. Konvalinka¹
¹Nephrology, Toronto General Hospital Research Institute and Multi-Organ Transplant, University Health Network, Toronto, ON, Canada, ²Lung Transplantation, Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada
*Purpose: Chronic lung allograft dysfunction (CLAD) remains the leading cause of long-term mortality after lung transplant. Non invasive biomarkers that could assist in early diagnosis…